AI assistant
BioAge Labs, Inc. — Director's Dealing 2026
Feb 19, 2026
33722_dirs_2026-02-19_1dbe6155-ebb9-4931-be0d-36dc433bd4fa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BioAge Labs, Inc. (BIOA)
CIK: 0001709941
Period of Report: 2026-02-17
Reporting Person: Morgen Eric (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-02-17 | Stock Option (Right to Buy) | $19.63 | A | 110000 | Acquired | 2036-02-16 | Common Stock (110000) | Direct |
| 2026-02-17 | Stock Option (Right to Buy) | $19.63 | A | 12500 | Acquired | 2036-02-16 | Common Stock (12500) | Indirect |
Footnotes
F1: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F2: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the holder's continued service to the Issuer on each vesting date.
F3: Represents an employee stock option directly held by the reporting person's spouse.